Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)

HER2 Positive Metastatic Breast Cancer Clinical Trial

Official title:

A Randomised, Open-label, Parallel Controlled, Multicentre, Phase 3 Clinical Trial of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer:

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03080805
• Other study ID #: HR-BLTN-?-MBC
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: May 3, 2017
• Est. completion date: March 2021

Study information

• Verified date: June 2020
• Source: Jiangsu HengRui Medicine Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors. This study is a randomized,open-label,multi-center,active-controlled, parallel design study of the combination of pyrotinib and capecitabine versus Lapatinib plus capecitabine in HER2+ MBC patients, who have prior received taxane and trastuzumab.Patients will be randomized in a 1:1 ratio to one of the following treatment arms.Arm A: pyrotinib (400 mg once daily) + capecitabine (1000 mg/m^2 twice daily),Arm B: Lapatinib (1250 mg once daily) + capecitabine (1000 mg/m^2 twice daily).Patients will receive either arm of therapy until disease progression, unacceptable toxicity, or withdrawalof consent.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 240
• Est. completion date: March 2021
• Est. primary completion date: March 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Aged =18 and =70 years.

2. ECOG performance status of 0 to 1.

3. Life expectancy of more than 12 weeks.

4. According to RECIST 1.1, at least one measurable lesion exists

5. Histologically or cytologic confirmed HER2 positive metastatic breast cancer.

6. Prior treatment with trastuzumab (=2 cycles in metastatic setting, or

=3 months in adjuvant/neoadjuvant setting) and Taxane(=2 cycles in any setting or untill unendurable AE or progression during treatment).

7. Previously reveived =2 chemotherapy regimens in metastasis setting;

8. Required laboratory values including following parameters:

ANC: = 1.5 x 10^9/L; Platelet count: = 90 x 10^9/L; Hemoglobin: = 90 g/L; Total bilirubin: = 1.5 x upper limit of normal (ULN); ALT and AST: = 2 x ULN(patients with liver metastases: =5 x ULN); BUN and Creatinine:

= 1x ULN;CCR=50 mL/min;LVEF: = 50%;QTcF: < 450 ms (male),< 470 ms(female);

9. Signed informed consent.

Exclusion Criteria:

1. Received capecitabine in metastatic setting;

2. Received HER2 targeted tyrosine kinase inhibitor (including Lapatinib, Neratinib and Pyrotinib);

3. Cumulated dosage of Doxorubincin >400 mg/m^2 or Epirubicin >800 mg/m^2 or equal dosage of other anthracycline drugs in adjuvant/neoadjuvant/metastatic setting );

4. Received surgery,chemotherapy,radiotherapy or target therapy within 28 days prior to randomization. Received hormone therapy within 7 days prior to randomization;

5. Participated in other clinical trial within 28 days prior to randomization.

6. Known dihydro pyrimidine dehydrogenase(DPD)defect;

7. CT or MRI confirmed brain metastases;

8. Bone or skin lesion as unique target lesion;

9. Second malignancies within 5 years, except for cured skin basal cell carcinoma,carcinoma in-situ of uterine cervix and squamous-cell carcinoma;

10. Factors influencing the usage of oral administration (e.g. unable to swallow, chronic diarrhea and intestinal obstruction, etc.);

11. Uncontrolled third space effusion (such as pleural fluid and ascites) by drainage or other clinical intervention;

12. Receiving any other anti-tumour therapy after informed consent;

13. Unprogressed after or during the last anti-tumour therapy,according to RECIST1.1;

14. History of any kind of Heart disease,including 1)Angina pectoris; (2) Arrhythmia required medication or with clinical significance; (3) Myocardial infarction; (4) Heart failure; (5) Any other heart disease judged by researcher as not suitable for participating in this study, etc;

15. History of Immunodeficiency, acquired or congenital immunodeficiency (HIV positive) ,history of organ transplantation;

16. History of neurological or psychiatric disorders, including epilepsy or dementia;

17. Concomitant disease judged by investigators that may bring serious harm to the safety of patients or the completion of this study;

18. All female patients in breastfeeding period or in child-bearing period or with positive pregnancy test result or refusing to take a reliable method of birth control during the study;

19. Any other situations judged by investigator as not suitable for participating in this study.

Related Conditions & MeSH terms

• Breast Neoplasms
• HER2 Positive Metastatic Breast Cancer

Intervention

Drug:
• Pyrotinib Plus Capecitabine
pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/ m^2 BID)
• Lapatinib Plus Capecitabine
Lapatinib (1250 mg once daily)+ capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)

Locations

Country	Name	City	State
China	Cancer Institute and Hospital,Chinese Academy of Medical Science	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival(PFS)	From infromed consent to progression or death	Estimated 10 months
Secondary	Safety: AE	AE	AE recorded from infromed consent to 28 days after treatment completion
Secondary	Overall Survival (OS)	From infromed consent to death	Estimated 30 months
Secondary	Objective Response Rate (ORR)	CR+PR	Estimated 10 months
Secondary	Time to Progression (TTP)	From infromed consent to progression	Estimated 10 months
Secondary	Duration of Response (DOR)	CR+PR+SD	Estimated 10 months
Secondary	Clinical Benefit rate (CBR)	CR+PR+SD=24 weeks	Estimated 10 months